Advertisement

Brigham and Women’s Hospital and Duke Clinical Research Institute have reduced the scope of two large-scale Phase 3 trials evaluating investigational anti-clotting medication vorapaxar.

The two institutions said in a press release that they are making the move in response to recommendations by the independent Data Safety Monitoring Board.

SOURCE

Advertisement
Advertisement